5-Day Sell-Off Sends McKesson Stock Down -7%
McKesson (MCK) – a healthcare supply chain and pharmacy technology solutions provider – hit a 5-day losing streak, with cumulative losses over this period amounting to -7%. The company’s market cap has crashed by about $8.2 Bil over the last 5 days and currently stands at $108 Bil.
Is this opportunity or trap? There is a near-equal mix of good and bad in MCK stock given its overall Moderate operating performance and financial condition. Considering stock’s Low valuation we think it is Attractive (For details, see Buy or Sell MCK).
But here is the interesting part. You are reading about this -7% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- Beyond the Rally: What Could Support Or Stall ArcelorMittal
- Same Intuit, Half the Price. What’s Actually Going On?
- How Oracle Stock Rises To $300
- At 175x Earnings, Palantir Isn’t Really As Expensive As It Looks
- What’s Really Fueling The Amazon Stock Rally?
- Where Could The Next Breakout for Oracle Stock Come From
The following table summarizes the return for MCK stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MCK | S&P 500 |
|---|---|---|
| 1D | -1.0% | 1.1% |
| 5D (Current Streak) | -7.0% | -1.8% |
| 1M (21D) | -7.4% | -4.8% |
| 3M (63D) | 8.3% | -2.9% |
| YTD 2026 | 7.0% | -3.9% |
| 2025 | 44.5% | 16.4% |
| 2024 | 23.7% | 23.3% |
| 2023 | 24.0% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 38 S&P constituents with 3 days or more of consecutive gains and 49 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 32 | 13 |
| 4D | 2 | 18 |
| 5D | 2 | 13 |
| 6D | 2 | 5 |
| 7D or more | 0 | 0 |
| Total >=3 D | 38 | 49 |
Key Financials for McKesson (MCK)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $309.0 Bil | $359.1 Bil |
| Operating Income | $4.2 Bil | $4.8 Bil |
| Net Income | $3.0 Bil | $3.3 Bil |
Last 2 Fiscal Quarters:
| Metric | 2026 FQ2 | 2026 FQ3 |
|---|---|---|
| Revenues | $103.2 Bil | $106.2 Bil |
| Operating Income | $1.5 Bil | $1.7 Bil |
| Net Income | $1.1 Bil | $1.2 Bil |
The losing streak MCK stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.